Return to homepagePandemic Pact

University of Oxford and Serum Institute of India

  • Funded by Coalition for Epidemic Preparedness Innovations (CEPI)
  • Total publications:0 publications

Grant number: CEPI-1787

Grant search

Key facts

  • Disease

    Disease X

  • Start & end year

    2026

  • Known Financial Commitments (USD)

    $8,600,000

  • Funder

    Coalition for Epidemic Preparedness Innovations (CEPI)

  • Research Location

    99

  • Lead Research Institution

    University of Oxford and Serum Institute of India

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

CEPI has committed initial funding of up to US$8.6 million to fund preclinical testing and other development activities to rapidly prepare for Phase 1 trials of a vaccine based on the University of Oxford's ChAdOx1 platform, which underpinned the Oxford/AstraZeneca COVID-19 vaccine. The funding will also support creation of a Master Virus Seed stock and manufacturing of clinical-grade doses at SII under CEPI’s pre-existing agreement with the company. This programme leverages CEPI's existing strategic partnership with the University of Oxford and SII's participation in CEPI's Vaccine Manufacturing Facility Network.